Wigs and Humor
Sometimes Megan Woodmansee is a redhead or brunette.
But life as a blonde isn't bad either, she jokes.
Having fun with her wigs is one way the 21-year-old college student is coping as she battles non-Hodgkin's lymphoma. Another way she is dealing with her cancer is speaking out about it so that others will learn from her experience. Her message for young people about cancer is that it can happen to anyone, even someone vibrant like herself.
About her own condition, she's optimistic. Last week, she completed chemotherapy treatments that began in December.
She and her doctors hope tests will reveal that her cancer is gone and treatments are over. She wants to return this summer to just being a college girl studying human communications.
More from the Arizona Central
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
